CEL SCI CORP

CVM · NYSE · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $0.0B · 44 employees
323
SEC Filings
$1.54
Close 2026-05-29
44
Employees

Business Summary

CEL-SCIs PRODUCT CANDIDATES CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the bodys natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of cert...

Latest Stock Quote

CVM 2026-05-29 $1.54 O:$1.46 H:$1.5704 L:$1.46 Vol:0.2M VWAP:$1.528
origin leaf: 404fecc979b1628b4a55c7803dff0c49811c0d2b69bafd00f0838711d60912b6

Next Earnings

Q2 FY2026 — expected 2026-08-22

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-12-292025-09-300001654954-25-014303EDGAR62K words
2025-01-132024-09-300001654954-25-000288EDGAR—
2023-12-212023-09-300001654954-23-015877EDGAR—
2022-12-272022-09-300001654954-22-016959EDGAR—
2021-12-212021-09-300001654954-21-013417EDGAR—
2020-12-292020-09-300001654954-20-013975EDGAR—
2019-12-162019-09-300001654954-19-013971EDGAR—
2018-12-192018-09-300001654954-18-014104EDGAR—
2017-12-292017-09-300001654954-17-011928EDGAR—
2016-12-142016-09-300001654954-16-004867EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-172025-12-310001654954-26-001319EDGAR17K words
2025-08-142025-06-300001654954-25-009568EDGAR—
2025-05-142025-03-310001654954-25-005606EDGAR—
2025-02-142024-12-310001654954-25-001578EDGAR—
2024-08-142024-06-300001654954-24-010651EDGAR—
2024-05-152024-03-310001654954-24-006411EDGAR—
2024-02-142023-12-310001654954-24-001793EDGAR—
2023-08-102023-06-300001654954-23-010485EDGAR—
2023-05-122023-03-310001654954-23-006371EDGAR—
2023-02-142022-12-310001654954-23-001725EDGAR—
2022-08-122022-06-300001654954-22-011196EDGAR—
2022-05-132022-03-310001654954-22-006762EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2025-11-240001654954-25-013412EDGAR29K words
2025-11-050001654954-25-012607EDGAR—
2025-08-290001654954-25-010184EDGAR—
2025-08-250001654954-25-009966EDGAR—
2025-07-140001654954-25-008033EDGAR—
2025-05-230001654954-25-006091EDGAR—
2025-05-190001654954-25-005876EDGAR—
2025-03-180001654954-25-002970EDGAR—
2024-12-310001654954-24-016019EDGAR—
2024-11-150001654954-24-014554EDGAR—

323 total filings indexed. 291 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0000725363
TickerCVM
ExchangeNYSE
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedCO
Websitehttps://www.cel-sci.com
Listed1983-12-08

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: b98c23efe201015e385f4e46698660f7a2cbf4eb55d7d0071ebda825de5786c1
parent: 80c5333e804911912372bb514a9c38bf78dc95a72afc353422acaa5e2cfa03e0
content hash: e7fdd1f1ca8a3f90af5c9f44cb5b75b7a17d90b591885bbd234940d5b10e0682
signed: 2026-06-02T19:00:49.012Z
sources: 23 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf